Brief: BioSenic Signs New Binding Term Sheet With Phebra PTY Ltd

Biosenic SA

15/01/2024 07:08

Jan 15 (Reuters) - Biosenic SA  BIOS.BR :
    * BIOSENIC REACHES AGREEMENT ON A BINDING TERM SHEET WITH
PHEBRA
PTY LTD. WITH RESPECT TO THE DEVELOPMENT OF THE FIRST ORAL
FORMULATION OF  ARSENIC TROXIDE FOR CGVHD TREATMENT
    * NEW BINDING TERM SHEET HAS BEEN SIGNED TO ADAPT TERMS OF
TWO
PREVIOUS AGREEMENTS UNDER WHICH PHEBRA GRANTED MEDSENIC SAS
    * PHEBRA PTY LTD. AGREES THAT NET PROFIT ALLOCATION AS
STATED IN
INITIAL MDA WILL BE DELETED FOR SALES REVENUES AND PROFITS
GENERATED FROM SALE OF PRODUCT, RESTRICTED TO INDICATION CGVHD
    * PHEBRA PTY LTD. ALSO AGREES TO COVER COSTS OF MAINTAINING
AND
UPDATING DRUG SUBSTANCE FILE TO COMPLY WITH RULES OF ALL ACTIVE
TERRITORIES
    * MEDSENIC WILL HAVE RIGHT TO ESTABLISH AN AUSTRALIAN ENTITY
TO
USE OATO PATENTS FOR CGVHD INDICATION
    * AUSTRALIAN ENTITY WILL NOT COMMERCIALLY COMPETE WITH
PHEBRA PTY
LTD., PARTICULARLY IN FIELD OF APL (ACUTE PROMYELOCYTIC
LEUKEMIA) CANCER TREATMENT
    * TO TAKE INTO ACCOUNT THESE COSTS FOR PHEBRA PTY LTD.,
COST-OF-GOODS FOR MEDSENIC FINAL CLINICAL OATO PRODUCT WILL BE
INCREASED BY A MARK-UP OF 20%

Source text for Eikon:  ID:nGNE8qZtXR 
Further company coverage:  BIOS.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))